title: Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
abstract: The Bcr-Abl kinase inhibitor imatinib is remarkably effective in chronic myelogenous leukemia (CML), although drug resistance is an emerging problem. Myeloid Src family kinases such as Hck and Lyn are often overexpressed in imatinib-resistant CML cells that lack Bcr-Abl mutations. Here we tested whether Hck overexpression is sufficient to induce imatinib resistance using both wild-type Hck and a mutant (Hck-T338A) that is uniquely sensitive to the pyrazolo-pyrimidine inhibitor, NaPP1. Expression of either kinase in K562 CML cells caused resistance to imatinib-induced apoptosis and inhibition of soft-agar colony formation. Treatment with NaPP1 restored sensitivity to imatinib in cells expressing T338A but not wild-type Hck, demonstrating that resistance requires Hck kinase activity. NaPP1 also reduced Hck-mediated phosphorylation of Bcr-Abl at sites that may affect imatinib sensitivity exclusively in cells expressing Hck-T338A. These data show that elevated Src family kinase activity is sufficient to induce imatinib resistance through a mechanism that may involve phosphorylation of Bcr-Abl.
authors.affiliation: Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvainia 15219, USA.
authors.forename: Teodora
authors.initials: T
authors.lastname: Pene-Dumitrescu
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Smithgall
mesh_terms: D000818:Animals; D017209:Apoptosis; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism*; D008957:Models, Genetic; D009154:Mutation; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology*; D011487:Protein Conformation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D019061:src-Family Kinases / Q000378:metabolism*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; C406060:abl-bcr fusion protein, human; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D019061:src-Family Kinases
references.citation: Science. 2000 Sep 15;289(5486):1938-42
references.pmid: 10988075
references.citation: N Engl J Med. 1999 Jul 15;341(3):164-72
references.pmid: 10403855
references.citation: EMBO J. 2002 Nov 1;21(21):5766-74
references.pmid: 12411494
references.citation: J Biol Chem. 1999 Sep 10;274(37):26579-83
references.pmid: 10473622
references.citation: Nat Struct Mol Biol. 2008 Oct;15(10):1109-18
references.pmid: 18794843
references.citation: J Natl Cancer Inst. 2008 Jul 2;100(13):926-39
references.pmid: 18577747
references.citation: J Biol Chem. 2000 Jan 28;275(4):2721-6
references.pmid: 10644735
references.citation: Exp Hematol. 2003 Jun;31(6):504-11
references.pmid: 12829026
references.citation: Science. 2001 Aug 3;293(5531):876-80
references.pmid: 11423618
references.citation: Proc Soc Exp Biol Med. 1981 Apr;166(4):546-50
references.pmid: 7194480
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Cell. 1995 Sep 22;82(6):981-8
references.pmid: 7553858
references.citation: J Biol Chem. 2006 Oct 13;281(41):30907-16
references.pmid: 16912036
references.citation: Curr Biol. 1998 Feb 26;8(5):257-66
references.pmid: 9501066
references.citation: Blood. 2003 Jan 15;101(2):690-8
references.pmid: 12509383
references.citation: Cell. 2003 Mar 21;112(6):831-43
references.pmid: 12654249
references.citation: N Engl J Med. 2003 Oct 9;349(15):1451-64
references.pmid: 14534339
references.citation: Blood. 2007 Dec 1;110(12):4055-63
references.pmid: 17720881
references.citation: Genes Dev. 1999 Sep 15;13(18):2400-11
references.pmid: 10500097
references.citation: Cancer Res. 1996 Aug 1;56(15):3589-96
references.pmid: 8758931
references.citation: Oncogene. 1993 Jan;8(1):117-24
references.pmid: 7678701
references.citation: J Biol Chem. 2000 Jun 16;275(24):18581-5
references.pmid: 10849448
references.citation: Chem Biol. 1999 Sep;6(9):671-8
references.pmid: 10467133
references.citation: Oncogene. 2008 Nov 27;27(56):7055-69
references.pmid: 18794796
references.citation: Oncogene. 2002 Nov 21;21(53):8075-88
references.pmid: 12444544
references.citation: Cancer Res. 2008 Dec 1;68(23):9809-16
references.pmid: 19047160
references.citation: J Biol Chem. 2000 Nov 10;275(45):35631-7
references.pmid: 10964922
references.citation: Cell. 1993 Oct 8;75(1):175-85
references.pmid: 8402896
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1386-91
references.pmid: 19164531
references.citation: J Mol Biol. 2008 Nov 7;383(2):414-23
references.pmid: 18775435
references.citation: J Biol Chem. 1997 Jul 18;272(29):17899-902
references.pmid: 9218412
references.citation: Mol Cell. 1999 May;3(5):629-38
references.pmid: 10360179
references.citation: Mol Cell. 1999 May;3(5):639-48
references.pmid: 10360180
references.citation: Trends Cell Biol. 2001 Apr;11(4):167-72
references.pmid: 11306297
references.citation: EMBO J. 2002 Feb 15;21(4):514-24
references.pmid: 11847100
references.citation: Nat Struct Biol. 2002 May;9(5):365-9
references.pmid: 11976726
references.citation: Blood. 2008 Apr 1;111(7):3821-9
references.pmid: 18235045
references.citation: Cancer Res. 2004 Jan 15;64(2):672-7
references.pmid: 14744784
references.citation: Cancer Res. 2001 Oct 1;61(19):7318-24
references.pmid: 11585772
references.citation: Cell. 1984 Jan;36(1):93-9
references.pmid: 6319012
references.citation: J Biol Chem. 2006 Sep 15;281(37):27029-38
references.pmid: 16849330
references.citation: J Biol Chem. 2005 Dec 9;280(49):40832-7
references.pmid: 16210316
references.citation: Cancer Res. 2007 Dec 15;67(24):11576-84
references.pmid: 18089786
references.citation: Blood. 2000 Nov 15;96(10):3343-56
references.pmid: 11071626
references.citation: J Mol Biol. 2004 Nov 5;343(5):1255-68
references.pmid: 15491611
references.citation: Cytokine Growth Factor Rev. 1997 Mar;8(1):63-79
references.pmid: 9174663
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17456-61
references.pmid: 15505216
references.citation: Nature. 2000 Sep 21;407(6802):395-401
references.pmid: 11014197
references.citation: Chem Biol. 2004 May;11(5):691-701
references.pmid: 15157880
references.citation: Biochim Biophys Acta. 1997 Dec 9;1333(3):F201-16
references.pmid: 9426204
references.citation: Oncogene. 1996 Dec 19;13(12):2589-94
references.pmid: 9000132
references.citation: J Biol Chem. 2001 Mar 2;276(9):6061-4
references.pmid: 11152665
references.citation: J Biol Chem. 1997 Dec 26;272(52):33260-70
references.pmid: 9407116
references.citation: Mol Cell. 2006 Mar 17;21(6):787-98
references.pmid: 16543148
references.citation: Oncogene. 2000 May 15;19(21):2523-31
references.pmid: 10851051
references.citation: Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44
references.pmid: 14708008
references.citation: EMBO J. 1994 Feb 15;13(4):764-73
references.pmid: 8112292
references.citation: Mol Cell Biol. 1991 Apr;11(4):1785-92
references.pmid: 2005881
references.citation: Leukemia. 2002 Nov;16(11):2190-6
references.pmid: 12399961
references.citation: Biochem Biophys Res Commun. 1999 Apr 2;257(1):129-38
references.pmid: 10092522
references.citation: Blood. 2008 Feb 1;111(3):1039-43
references.pmid: 17932248
references.citation: Nature. 1985 Jun 13-19;315(6020):550-4
references.pmid: 2989692
references.citation: Oncogene. 2008 Jun 19;27(27):3831-44
references.pmid: 18246120
references.citation: Oncogene. 2000 Mar 23;19(13):1684-90
references.pmid: 10763825
references.citation: Oncogene. 1996 Feb 15;12(4):839-46
references.pmid: 8632906
references.citation: Bioorg Med Chem. 2005 Apr 15;13(8):2825-36
references.pmid: 15781393